---
title: History of Indias pharmaceutical industry
videoId: WkylI-78U6c
---

From: [[asianometry]] <br/> 

## The Current State of India's Pharmaceutical Industry

The Indian economy is largely service-based, but pharmaceuticals stand out as a significant exception <a class="yt-timestamp" data-t="00:00:03">[00:00:03]</a>. As of 2020, India possesses the third-largest pharmaceutical industry by volume and the 11th largest by value, experiencing extremely rapid growth <a class="yt-timestamp" data-t="00:00:12">[00:00:12]</a>.

India is the world's largest provider of generic drugs <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>. The United States, for instance, relies on India for 40 percent of its generics <a class="yt-timestamp" data-t="00:00:24">[00:00:24]</a>. In 2020, India exported $16 billion more in pharmaceuticals than it imported <a class="yt-timestamp" data-t="00:00:30">[00:00:30]</a>. These exports adhere to the strict standards and regulations of many countries globally <a class="yt-timestamp" data-t="00:00:35">[00:00:35]</a>.

## Early Challenges Post-Independence

The story of India's pharmaceutical industry begins in 1947, with the country's independence <a class="yt-timestamp" data-t="00:01:19">[00:01:19]</a>. At this time, millions of Indians lacked access to basic drugs <a class="yt-timestamp" data-t="00:01:22">[00:01:22]</a>. Foreign entities almost completely controlled India's drug industry <a class="yt-timestamp" data-t="00:01:28">[00:01:28]</a>. Eight out of the top ten firms were Western multinationals, primarily from the UK, France, and Germany, holding a 90 percent market share <a class="yt-timestamp" data-t="00:01:33">[00:01:33]</a>.

Domestic Indian companies primarily focused their resources on marketing and distributing drugs made by others, rather than creating their own <a class="yt-timestamp" data-t="00:01:42">[00:01:42]</a>. Consequently, nearly every drug consumed by Indians had to be imported <a class="yt-timestamp" data-t="00:01:50">[00:01:50]</a>. Domestic drug prices were among the highest globally because 99% of these drugs were protected by patents, limiting access to only the wealthy <a class="yt-timestamp" data-t="00:01:52">[00:01:52]</a>.

## Government Intervention and Policy Changes

The Indian government made several attempts to address its over-reliance on foreign drug imports <a class="yt-timestamp" data-t="00:02:05">[00:02:05]</a>.

*   In 1954, the government established Hindustan Antibiotics Limited (HAL), a public sector pharmaceutical firm <a class="yt-timestamp" data-t="00:02:14">[00:02:14]</a>.
*   A few years later, they founded a second public firm, Indian Drugs and Pharmaceuticals Limited, in cooperation with the Soviets <a class="yt-timestamp" data-t="00:02:22">[00:02:22]</a>.

A pivotal moment occurred in the 1960s when the British pharmaceutical company ICI Pharmaceuticals developed propranolol, a high blood pressure medication <a class="yt-timestamp" data-t="00:02:31">[00:02:31]</a>. This drug, also used for anxiety and migraine prevention, was too expensive for use in India <a class="yt-timestamp" data-t="00:02:44">[00:02:44]</a>. An Indian company named Cipla began manufacturing a generic version for the Indian market <a class="yt-timestamp" data-t="00:02:47">[00:02:47]</a>. ICI complained to the Indian government about this <a class="yt-timestamp" data-t="00:02:54">[00:02:54]</a>. Cipla's R&D head, Yusuf Hamid, justified his actions to Prime Minister Indira Gandhi, who saw the merit in his argument and urged parliament to modify drug patent laws <a class="yt-timestamp" data-t="00:02:57">[00:02:57]</a>.

### [[impact_of_the_1970_indian_patent_act | The Patent Act of 1970]]

This advocacy led to the passing of the Patent Act of 1970, which catalyzed the revitalization of the Indian pharmaceutical industry <a class="yt-timestamp" data-t="00:03:12">[00:03:12]</a>.

The 1970 Patent Act aimed to achieve two goals:
1.  Guarantee low-cost access to drugs <a class="yt-timestamp" data-t="00:03:21">[00:03:21]</a>.
2.  Foster the development of an indigenous Indian pharmaceutical industry and encourage import substitution <a class="yt-timestamp" data-t="00:03:26">[00:03:26]</a>.

Prior Indian patent laws, last updated in 1872, were based on British intellectual property (IP) law and specifically protected products, such as chemical compounds <a class="yt-timestamp" data-t="00:03:36">[00:03:36]</a>. The 1970 Act replaced this with a system that protected the *process* of making a drug rather than the *product* itself <a class="yt-timestamp" data-t="00:03:53">[00:03:53]</a>. Additionally, the act set time limits on these process patents to about five to seven years after filing, shorter than the 15 years under the old law <a class="yt-timestamp" data-t="00:04:07">[00:04:07]</a>. The Indian patent office also gained the authority to compel patent holders to license their patents at a reasonable rate if they were not being used in a socially beneficial way <a class="yt-timestamp" data-t="00:04:17">[00:04:17]</a>. This new system created vast opportunities for the Indian pharmaceutical industry, allowing for the reverse engineering of nearly every popular drug import <a class="yt-timestamp" data-t="00:04:31">[00:04:31]</a>.

## Understanding the Pharmaceutical Production Value Chain

The pharmaceutical production value chain comprises four main activities:
1.  **Discovery**: The process of finding new drugs <a class="yt-timestamp" data-t="00:4:59">[00:4:59]</a>. This involves generating potential molecules (leads) and testing their efficacy through in vitro (petri dish) and then in vivo (live animal) tests <a class="yt-timestamp" data-t="00:05:08">[00:05:08]</a>. These tests can take years, with only a small percentage progressing to the next stage <a class="yt-timestamp" data-t="00:05:28">[00:05:28]</a>.
2.  **Clinical Trials**: Human clinical trials have stringent standards, procedures, and oversight, making them extremely expensive <a class="yt-timestamp" data-t="00:05:37">[00:05:37]</a>. Failures are common, as seen with Stemcentrx, a cancer drug startup that sold to AbbVie for $5.8 billion but whose drugs later failed in clinical trials, leading to a $5 billion write-off <a class="yt-timestamp" data-t="00:05:50">[00:05:50]</a>.
3.  **Production**: After clinical trial approval, drugs are produced <a class="yt-timestamp" data-t="00:06:31">[00:06:31]</a>. There are two types:
    *   **Bulk drug manufacturing**: Producing the active compounds on an industrial scale <a class="yt-timestamp" data-t="00:06:40">[00:06:40]</a>. This is technically sophisticated but generally less valuable than other parts of the value chain, requiring scale and cost control <a class="yt-timestamp" data-t="00:06:56">[00:06:56]</a>.
    *   **Formulation manufacturing**: Packaging active ingredients into pills, tablets, capsules, liquids, or injectables <a class="yt-timestamp" data-t="00:06:46">[00:06:46]</a>.
4.  **Marketing and Distribution**: Large pharmaceutical companies employ sales forces to build relationships with doctors and patients to sell prescriptions and recoup investment <a class="yt-timestamp" data-t="00:07:12">[00:07:12]</a>.

## Early Growth and Reverse Engineering

Managers and scientists in India's public sector laboratories recognized the opportunity presented by the modified patent law <a class="yt-timestamp" data-t="00:07:32">[00:07:32]</a>. The number of pharmaceutical firms in India more than doubled between 1970 and 1980 <a class="yt-timestamp" data-t="00:07:40">[00:07:40]</a>.

At this early stage, domestic Indian companies primarily reverse-engineered existing drugs by studying the production steps and making minor modifications to create new processes <a class="yt-timestamp" data-t="00:07:48">[00:07:48]</a>. This approach, though seemingly derivative, allowed domestic companies to gain significant competency in pharmaceuticals <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>. By the end of the 1980s, Indian pharmaceutical companies could manufacture almost any new molecule without needing the original innovator's recipes <a class="yt-timestamp" data-t="00:08:52">[00:08:52]</a>.

The time gap between the introduction of original innovations and Indian generics steadily decreased:
*   Ibuprofen, introduced globally in 1967, had its first Indian generic in 1973, a six-year lag <a class="yt-timestamp" data-t="00:09:15">[00:09:15]</a>.
*   Bayer introduced the antibiotic ciprofloxacin in 1986, but Indian firms had a generic version in just three years <a class="yt-timestamp" data-t="00:09:26">[00:09:26]</a>.

By 2006, Indian companies supplied 95% of the country's drugs, demonstrating the success of import substitution <a class="yt-timestamp" data-t="00:09:56">[00:09:56]</a>.

## Drawbacks of the 1970 Patent Act

Despite its successes, the 1970 patent change had drawbacks <a class="yt-timestamp" data-t="00:10:05">[00:10:05]</a>. The Indian pharmaceutical industry it fostered was high in volume but low in value <a class="yt-timestamp" data-t="00:10:11">[00:10:11]</a>. With low barriers to entry and minimal capital needed, the industry grew to around 16,000 pharmaceutical companies by 1990 <a class="yt-timestamp" data-t="00:10:17">[00:10:17]</a>.

Companies focused on producing as many molecules as cheaply as possible, leading to extremely low margins and vast overcapacity, necessitating massive scale for profitability <a class="yt-timestamp" data-t="00:10:27">[00:10:27]</a>. The industry became highly fragmented, with up to 100 brands for a single molecule <a class="yt-timestamp" data-t="00:10:42">[00:10:42]</a>. Without resources, incentives, or protections for it, the domestic industry did not invest significantly in R&D or produce many new drugs <a class="yt-timestamp" data-t="00:10:53">[00:10:53]</a>. By the 1990s, about 40% of Indian drug production was for export, but these were largely low-value products, locking Indian companies out of more lucrative markets <a class="yt-timestamp" data-t="00:11:04">[00:11:04]</a>.

## [[evolution_from_generic_drugs_to_innovation | Evolution from Generic Drugs to Innovation]]: The TRIPS Agreement

In 1992, India signed the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), a major milestone for the industry <a class="yt-timestamp" data-t="00:11:21">[00:11:21]</a>. TRIPS mandated that the Indian government amend its patent policies to align with international trade standards, including recognizing product patents and granting exclusive marketing rights to new products <a class="yt-timestamp" data-t="00:11:37">[00:11:37]</a>.

Signing TRIPS was highly controversial within India, splitting the domestic industry into proponents and opponents of stricter IP protections <a class="yt-timestamp" data-t="00:11:51">[00:11:51]</a>. Opponents raised concerns about the lack of knowledge transfers and the historical negative impact of strong IP rights on the Indian populace <a class="yt-timestamp" data-t="00:12:02">[00:12:02]</a>.

Ultimately, the proponents prevailed. The international trade community gave India until 2005 to prepare its drug industry, leading to a gradual implementation of necessary changes, such as the exclusive marketing rights amendment to the 1970 patent law enacted in 1999 <a class="yt-timestamp" data-t="00:12:14">[00:12:14]</a>.

### Industry Adaptation (1992-2005)

From 1992 to 2005, the industry underwent a monumental shift from its long-standing successful model to a new, more profitable one <a class="yt-timestamp" data-t="00:13:35">[00:13:35]</a>.

Some firms, like Ranbaxy, Dr. Reddy's Laboratories (DRL), and Wockhardt, decided to invest in R&D, climb the value chain, and enter the drug discovery business <a class="yt-timestamp" data-t="00:12:52">[00:12:52]</a>.
*   From 1956 to 1987, India's pharmaceutical industry discovered and developed only 13 new drug compounds <a class="yt-timestamp" data-t="00:13:06">[00:13:06]</a>.
*   From 1991 to 2005, that number was seven <a class="yt-timestamp" data-t="00:13:13">[00:13:13]</a>.
*   Annual R&D spending growth accelerated from 4.9% before 1992 to 6.6% after <a class="yt-timestamp" data-t="00:13:19">[00:13:19]</a>.
*   Pharmaceutical drug patents filed by Indian institutions significantly increased: from 9 (1990-1994) to 48 (1995-1998), and further to 227 (1999-2002) <a class="yt-timestamp" data-t="00:13:37">[00:13:37]</a>.

The government also encouraged R&D through various schemes <a class="yt-timestamp" data-t="00:13:55">[00:13:55]</a>. In 1995, they founded government bodies to coordinate academic and commercial areas and created a pharmaceutical R&D support fund <a class="yt-timestamp" data-t="00:13:57">[00:13:57]</a>.

However, pursuing drug discovery was rare before 2005 due to its expense and time-consuming nature <a class="yt-timestamp" data-t="00:14:11">[00:14:11]</a>. Most Indian firms, particularly small to medium-sized ones, could not afford it; by 2005, smaller firms spent 1% or less of their revenue on R&D <a class="yt-timestamp" data-t="00:14:38">[00:14:38]</a>.

Many firms sought other ways to strengthen or diversify revenues:
*   Some invested in R&D for drug-adjacent fields, such as drug delivery <a class="yt-timestamp" data-t="00:14:52">[00:14:52]</a>.
*   Others expanded and strengthened different parts of the value chain, like marketing and production <a class="yt-timestamp" data-t="00:15:01">[00:15:01]</a>.
*   Strategic collaborations with multinationals became common <a class="yt-timestamp" data-t="00:15:07">[00:15:07]</a>. Zydus Cadila, for instance, made deals with companies in France, Cuba, Switzerland, and the United States <a class="yt-timestamp" data-t="00:15:11">[00:15:11]</a>. Biocon, a biopharmaceutical company, also signed deals with large companies like Novartis <a class="yt-timestamp" data-t="00:15:22">[00:15:22]</a>. A joint venture with the Cuban Center of Molecular Immunology helped Biocon gain competency to develop the first new monoclonal antibody treatment by an Indian pharmaceutical company <a class="yt-timestamp" data-t="00:15:30">[00:15:30]</a>.
*   Other companies pursued mergers and acquisitions to scale up and match the size of Western multinationals <a class="yt-timestamp" data-t="00:15:43">[00:15:43]</a>.

## Shift to the Export Market

TRIPS significantly pushed India's pharmaceutical companies towards the export market <a class="yt-timestamp" data-t="00:16:01">[00:16:01]</a>. Once the industry met its IP regulation responsibilities, the global market became accessible <a class="yt-timestamp" data-t="00:16:09">[00:16:09]</a>. Today, India's generics industry is highly internationally competitive due to lower costs and expertise gained from fierce domestic competition <a class="yt-timestamp" data-t="00:16:15">[00:16:15]</a>. A favorable generic drug regulatory environment, aided by the U.S. Hatch-Waxman Act of 1984, which eased FDA approval for generics, also contributed to this success <a class="yt-timestamp" data-t="00:16:27">[00:16:27]</a>.

Export intensity grew significantly:
*   Dr. Reddy's Laboratories increased its export ratio of overall revenue from 53% (2000-2005) to 74% (2012-2017) <a class="yt-timestamp" data-t="00:16:39">[00:16:39]</a>.
*   Marksans Pharma's export ratio soared from 21.2% (2000-2005) to 97.5% (2012-2017) <a class="yt-timestamp" data-t="00:16:53">[00:16:53]</a>.
The entire industry saw an average export intensity growth rate of about 13% after the 2005 TRIPS implementation <a class="yt-timestamp" data-t="00:17:04">[00:17:04]</a>. The industry is nearly eight times its size since then, with sales across North America, Africa, and Asia <a class="yt-timestamp" data-t="00:17:13">[00:17:13]</a>.

## Current Concerns

A significant concern for the Indian pharmaceutical industry is its concurrent [[dependence_on_china_for_active_pharmaceutical_ingredients | dependence on China for active pharmaceutical ingredients (APIs)]], which are the most critical raw materials for finished drugs <a class="yt-timestamp" data-t="00:17:21">[00:17:21]</a>. For example, acetaminophen is Tylenol's active ingredient <a class="yt-timestamp" data-t="00:17:36">[00:17:36]</a>.

India relies on China for 70% of its API imports <a class="yt-timestamp" data-t="00:17:40">[00:17:40]</a>. Imports of Chinese APIs, especially antibiotics, have tripled since 2005 <a class="yt-timestamp" data-t="00:17:46">[00:17:46]</a>. India used to produce these domestically but lost market share in the 1990s when Chinese products were 40% cheaper <a class="yt-timestamp" data-t="00:17:54">[00:17:54]</a>. Even today, with higher Chinese labor costs, the price gap remains about 20% <a class="yt-timestamp" data-t="00:18:03">[00:18:03]</a>.

This industrial weakness became particularly evident in 2020 when China's lockdowns led to stock shortages and restricted exports of certain ingredients for virus medicines to India <a class="yt-timestamp" data-t="00:18:11">[00:18:11]</a>. Given ongoing geopolitical tensions between China and India, the Indian industry and government should collaborate to address these shortcomings with new import substitution policies for APIs <a class="yt-timestamp" data-t="00:18:25">[00:18:25]</a>.

## Global Influence and Future Role

India's pharmaceutical success has been observed by other countries, who noted how the 1970 Indian Patent Act helped lower drug costs and reduce multinational control over domestic markets <a class="yt-timestamp" data-t="00:18:41">[00:18:41]</a>. Ironically, as India shifted away from process-based patents, other countries began moving towards them <a class="yt-timestamp" data-t="00:18:54">[00:18:54]</a>.

The Indian pharmaceutical industry's current standing is largely attributable to the strategic removal and re-application of IP rights <a class="yt-timestamp" data-t="00:19:03">[00:19:03]</a>. It serves as a prime example of market-driven reform spurred by environmental changes, adapting based on what was right for them at the time rather than adhering to rigid ideologies <a class="yt-timestamp" data-t="00:19:09">[00:19:09]</a>. While some concerns remain, India's pharmaceutical industry is poised to play a crucial role in addressing global health issues in the future <a class="yt-timestamp" data-t="00:19:31">[00:19:31]</a>.